News
Your source for the latest updates, breakthroughs, and insights in drug development and manufacturing. Explore our featured stories, press releases, and event announcements to stay informed about our innovations and contributions to drug development and manufacturing advancements.
Avance Biosciences NGS Center of Excellence: Comprehensive Sequencing Solutions for Biologics, Gene, and Cell Therapy Development
Avance Biosciences’ NGS Center of Excellence delivers comprehensive sequencing solutions, including short-read, long-read, and advanced single-cell platforms. Our regulatory-compliant workflows support biologics, gene, and cell therapy programs with high-quality data, enabling informed development...
Aug 18-21 The BioProcessing Summit – 2025
Avance Biosciences™ will not only be exhibiting (booth #516), but also presenting two posters as part of the Next-Generation Analytical Methods program: Genome-wide Mapping of CRISPR-Cas Off-Target Cleavage Sites via GUIDE-Seq & Digitally Secure Sequencing: Implementing Part 11-Ready NGS Data Security in a CRO Environment...
Case Study: Quantifying In Vivo Gene Editing in Preclinical Tissues via NGS Amplicon-Seq
To support IND-enabling studies, a biotech company needed precise measurement of in vivo gene-editing efficiency in preclinical rat tissues. Avance Biosciences delivered a fully validated NGS amplicon sequencing assay capable of detecting edits as low as 1%, enabling accurate quantification across multiple tissues and guiding data-driven development decisions.
Case Study: Ensuring Plasmid Sequence Fidelity and Purity by NGS for IND-Enabling Drug Substance Release
When a gene therapy company needed to verify plasmid identity, purity, and integrity for an IND submission, Avance Biosciences delivered a validated NGS-based solution. The assay enabled low-level variant detection and trace contaminant analysis, supporting FDA compliance and lot release.
Case Study: Ensuring Plasmid Sequence Fidelity and Purity by NGS for IND-Enabling Drug Substance Release
When a gene therapy company needed to verify plasmid identity, purity, and integrity for an IND submission, Avance Biosciences delivered a validated NGS-based solution. The assay enabled low-level variant detection and trace contaminant analysis, supporting FDA compliance and lot release.
Avance New Site Tier One Commissioning Change Notification
Avance Biosciences is proud to announce the partial commissioning of our new GMP facility at 5500 Northwest Central Drive in Houston, Texas. Effective July 21, 2025, select Biologics Quality Control services, including Microbiology and Sanger sequencing, will transition from our West Little York site to this new location. Please begin shipping samples directly to the new facility as we continue to expand our capabilities to better serve our clients.